Benefits
Supports Immune Cell Function
Vitamin C concentrates in neutrophils, lymphocytes, and phagocytes, supporting normal immune cell function, chemotaxis, and oxidative-burst regulation. Liposomal delivery may help maintain adequate plasma levels with smaller doses.
Enhanced Plasma Bioavailability
Liposomal ascorbate has been shown in pharmacokinetic studies to produce higher plasma vitamin C concentrations than unencapsulated oral ascorbic acid, particularly at gram-level doses where standard ascorbate absorption plateaus.
Supports Collagen Synthesis
Vitamin C is a cofactor for prolyl- and lysyl-hydroxylase enzymes essential for stable collagen formation, supporting skin, tendon, ligament, vascular, and gum integrity.
Antioxidant Defense
As a water-soluble antioxidant, vitamin C neutralizes reactive oxygen species and helps regenerate oxidized vitamin E, contributing to integrated antioxidant networks within cells and plasma.
Gentler on the GI Tract
Encapsulation may reduce the osmotic load that causes loose stools or cramping with high-dose ascorbic acid, making liposomal forms easier to tolerate at gram-level intakes.
Mechanism of action
Liposomal Encapsulation
Phosphatidylcholine bilayers shield ascorbate from gastric degradation and may facilitate uptake via lymphatic and transcellular routes, bypassing some saturation limits of sodium-dependent vitamin C transporters.
Cofactor for Hydroxylases
Vitamin C reduces iron at the active site of prolyl- and lysyl-hydroxylases, enabling collagen, carnitine, and neurotransmitter synthesis.
Electron Donor / ROS Scavenger
Ascorbate donates electrons to neutralize superoxide, hydroxyl, and peroxyl radicals, and regenerates oxidized α-tocopherol back to its active form.
Immune Modulation
Vitamin C supports interferon production, phagocyte oxidative burst, and lymphocyte proliferation, with the highest tissue concentrations found in immune cells.
Clinical trials
Randomized, placebo-controlled, repeated-measures study comparing plasma vitamin C kinetics after 4 g placebo, oral ascorbate, oral liposomal ascorbate, or intravenous ascorbate on four separate visits.
11 overweight/obese adults aged 45-70.
Liposomal oral delivery produced higher circulating vitamin C concentrations than unencapsulated oral ascorbate but lower than IV. All three vitamin C treatments provided comparable protection against an ex vivo ischemia-reperfusion oxidative-stress challenge. Supports liposomal forms as an intermediate-bioavailability oral option.
Scoping review identifying available studies on liposomal vitamin C formulations and bioavailability outcomes, with recommendations for future research methodology.
Aggregated trials across diverse adult populations.
Evidence base for liposomal vitamin C is small and heterogeneous; some trials show modest plasma-AUC advantages over unencapsulated ascorbate, while others find equivalence. The field lacks large, head-to-head, branded-formulation trials at standardized doses.